Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Relative Risk01:12

Relative Risk

2.1K
Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
2.1K
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

4.2K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
4.2K
Factors Affecting the Risk of Infection01:26

Factors Affecting the Risk of Infection

13.5K
The hosts' susceptibility to infection depends on several factors. The integrity of the skin and mucous membranes helps protect the body against microbial attacks. When the skin is altered, the chance of infection, limb loss, and even death increases.
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...
13.5K
Therapeutic Index01:13

Therapeutic Index

6.8K
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
6.8K
Therapeutic Communication01:30

Therapeutic Communication

8.0K
Communication is a lifelong learning process. Through therapeutic communication, nurses can collect relevant assessment data, provide education and counseling, and interact during nursing interventions. Sending and receiving messages occur through verbal and nonverbal communication techniques and can happen separately or simultaneously.
Verbal communication depends on language or a prescribed way of using words so that people can share information effectively. The critical aspects of verbal...
8.0K
Persuasion Strategies01:52

Persuasion Strategies

43.5K
Researchers have tested many persuasion strategies, including the foot-in-the door and the door-in-the-face techniques, in a variety of contexts. Ultimately, the principles are effective in selling products and changing people’s attitude, ideas, and behaviors (Cialdini & Goldstein, 2004).
43.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Response profile and long-term outcomes in Cyclin D1-overexpressing multiple myeloma: insights from the CASSIOPEIA trial.

Blood cancer journal·2026
Same author

Expression profile of CASSIOPEIA patients refines prognostic value of MRD negativity in multiple myeloma.

Blood cancer journal·2026
Same author

PKMYT1 is a Targetable Vulnerability in del(17p) High-Risk Multiple Myeloma.

Blood·2026
Same author

Does minimal residual disease matter in t(11;14) myeloma?

Blood·2026
Same author

FDG-PET medullary total tumor volume highlights high-risk patients with newly diagnosed multiple myeloma in CASSIOPEIA trial.

Blood advances·2026
Same author

Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French study.

Blood advances·2026
Same journal

Present and Emerging Strategies for Disease Assessment in Hodgkin Lymphoma.

Cancer journal (Sudbury, Mass.)·2026
Same journal

Nodular Lymphocyte-predominant Hodgkin Lymphoma: Incidence, Pathogenesis, Management.

Cancer journal (Sudbury, Mass.)·2026
Same journal

Management of Classic Hodgkin Lymphoma in Special Clinical Situations.

Cancer journal (Sudbury, Mass.)·2026
Same journal

Older Patients With Hodgkin Lymphoma: A Contemporary Review.

Cancer journal (Sudbury, Mass.)·2026
Same journal

Adolescent and Young Adult Patients With Classical Hodgkin Lymphoma: A Review as a Case Study in AYA Cancer Care.

Cancer journal (Sudbury, Mass.)·2026
Same journal

Hodgkin Lymphoma: Management of Patients Who Fail Primary Therapy.

Cancer journal (Sudbury, Mass.)·2026
See all related articles

Related Experiment Video

Updated: Jan 30, 2026

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.6K

Risk-Based Therapeutic Strategies.

Jill Corre1, Hervé Avet-Loiseau

  • 1From the IUC-Oncopole and CRCT INSERM U1037, Toulouse, France.

Cancer Journal (Sudbury, Mass.)
|January 30, 2019
PubMed
Summary
This summary is machine-generated.

High-risk myeloma patients need tailored treatments based on genomic risk. A multiparametric approach using next-generation sequencing is crucial for personalized therapy and improved outcomes.

More Related Videos

High Throughput Characterization of Adult Stem Cells Engineered for Delivery of Therapeutic Factors for Neuroprotective Strategies
09:19

High Throughput Characterization of Adult Stem Cells Engineered for Delivery of Therapeutic Factors for Neuroprotective Strategies

Published on: January 4, 2015

11.2K
Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
19:15

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale

Published on: August 25, 2014

88.0K

Related Experiment Videos

Last Updated: Jan 30, 2026

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.6K
High Throughput Characterization of Adult Stem Cells Engineered for Delivery of Therapeutic Factors for Neuroprotective Strategies
09:19

High Throughput Characterization of Adult Stem Cells Engineered for Delivery of Therapeutic Factors for Neuroprotective Strategies

Published on: January 4, 2015

11.2K
Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
19:15

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale

Published on: August 25, 2014

88.0K

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • Current multiple myeloma treatments do not account for genomic risk.
  • All patients receive similar therapies regardless of their specific risk profile.
  • This approach overlooks the need for more aggressive strategies in high-risk cases.

Purpose of the Study:

  • To review and discuss the optimal definition of genomic risk in multiple myeloma.
  • To advocate for a modern, multiparametric definition of genomic risk.
  • To explore the integration of minimal residual disease and next-generation sequencing in risk-based treatment adaptation.

Main Methods:

  • Literature review and expert discussion on current and future risk stratification methods.
  • Analysis of the role of minimal residual disease (MRD) in treatment management.
  • Evaluation of next-generation sequencing (NGS) as a tool for genomic risk assessment.

Main Results:

  • Existing therapeutic strategies for multiple myeloma are not risk-stratified by genomic factors.
  • A multiparametric definition of genomic risk is urgently required for personalized treatment.
  • Next-generation sequencing is poised to become essential for managing risk-based strategies.

Conclusions:

  • Optimal risk definition is critical for adapting multiple myeloma therapies.
  • Minimal residual disease monitoring will likely play a larger role in treatment decisions.
  • Despite advances in understanding the molecular landscape, targeted therapy options for myeloma remain limited.